Caris Molecular Intelligence® Tumor Profiling from Caris Life Sciences for Optimzing Cancer Therapy is now Offered by TherapySelect in Germany
We are glad to inform you that we now offer an evaluation of effectiveness of targeted and selected chemotherapeutic drugs by analyzing biomarkers.
The genetic material of a tumor can reveal potential opportunites which predict that a treatment is more likely to work. But there are more biomarkers that have been associated with treatment outcomes. They can be tested to give the physician the predictive information needed to make a treatment decision. Biomarkers in cancer can be alterations in the genetic code, differences in gene expression or changes in protein expression. No single technology can answer all of the necessary. Thus a multiplatform approach based on relevant, clinically proven biomarker to treatment associations makes the most sense.
Advantages of Caris Molecular Intelligence®
- The unique feature of Caris Molecular Intelligence® is the entire service as a whole. Multiple tumor profiling technologies – including Immunohistochemistry, Chromogenic in situ Hybridization (CISH), Fluorescence in situ Hybridization (FISH), Next-Generation Sequencing (NGS), Sanger Sequencing, Pyro Sequencing and Fragment Analysis – are used in order to detect and analyze biomarkers. Coupled with an exhaustive review of literature correlating biomarker to drug responses, Caris Molecular Intelligence® provides the information oncologists need in order to personalize cancer treatment based on the biology of their patient’s tumor.
- Caris has attained the highest available certifications of quality - CAP, CLIA, NYS and ISO15189.
- Caris has profiled more than 70,000 patients globally.
For further questions do not hesitate to contact our team.
Tel: +49 (0)6221-8936-152 oder
Emai l: firstname.lastname@example.org